Skip to main
PGNY
PGNY logo

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Progyny Inc. is well-positioned for continued growth within the expanding fertility insurance market, which is projected to potentially double in size, bolstered by the company's leadership and market share gains. The company is anticipating an increase in membership numbers for 2025 compared to 2024, supported by strong momentum in its selling season and favorable survey results indicating rising coverage rates among employers. Furthermore, Progyny's ability to attract new clients—adding 71 in 2024 and 80 in 2023—has led to significant growth in covered lives, demonstrating a robust demand for its comprehensive benefits solutions in fertility and women's health.

Bears say

Progyny Inc. is facing a negative outlook primarily due to a significant revision in revenue estimates, which has been lowered by 13.6% for 2025 to $1.2 billion from $1.4 billion, largely attributed to the loss of a key client that constituted 12% of revenue year-to-date. Additionally, the company's first-time guidance for 2028 of 20% revenue and 25% EBITDA growth appears to set expectations unreasonably high, especially in light of current competitive pressures and potential economic headwinds. Furthermore, projected margin pressures may arise from the loss of accounts that operated at lower margins, leading to increased concerns regarding utilization rates and the company's ability to maintain its competitive position in the market.

Progyny (PGNY) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 16 analysts, Progyny (PGNY) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.